Novo Nordisk has registered a first-in-human Phase I study of previously undisclosed obesity candidate NNC0721-8060, with a 142-participant program that will evaluate weight loss and include semaglutide alongside placebo despite the company keeping the asset’s target and modality under wraps
The randomized, double-blind, parallel-group study (NCT07767175) plans to enroll 142 adults aged 18–55 with a body mass index of 27.0–34.9 kg/m², divided across three parts with distinct primary endpoints: treatment-emergent adverse events in Parts A and B, and percentage change in body weight from baseline in Part C. A notable design feature is the inclusion of semaglutide (Ozempic/Wegovy) as an active comparator arm alongside placebo, providing an internal benchmark against an approved glucagon-like peptide-1 (GLP-1) receptor agonist from Novo Nordisk’s own portfolio. The trial is expected to begin in August 2026 at two ICON-operated early-phase sites in Lenexa, Kansas and San Antonio, Texas, with primary completion anticipated in September 2027.
Novo Nordisk has not publicly disclosed NNC0721-8060’s molecular target, mechanism, or modality, limiting assessment of how the program differs from the company’s existing and pipeline obesity therapies. No prior company announcement, scientific publication, or publicly disclosed preclinical data was identified, suggesting the trial registration represents the first substantive public emergence of the program
The inclusion of semaglutide alongside placebo is notable for a first-in-human program and should allow Novo Nordisk to contextualize early pharmacodynamic and weight-loss signals against an established therapy from its own portfolio. This design choice would allow Novo Nordisk to contextualize early efficacy signals against a well-characterized internal standard. The obesity pharmacology field is crowded at every stage of development, but without knowledge of NNC0721-8060’s target, meaningful competitive positioning against specific pipeline assets is not possible on the basis of available evidence.
With enrollment not yet open, the next milestone is initiation of dosing. The study’s September 2027 primary completion date should provide the first full clinical assessment of NNC0721-8060’s safety and pharmacology, as well as an initial indication of its effect on body weight
Access the AllSci platform to explore the science behind the news
Spot something wrong? Report an issue with this article
